Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Phase I trial of intracranial B7H3 CAR-T therapy in recurrent glioblastoma

Reena Thomas • 3 Jun 2025
ASCO 2025
Brain Tumor Glioblastoma Glioma B7H3-CART CAR-T

Reena Thomas, MD, PhD, Stanford University, Stanford, CA, discusses a Phase I trial (NCT05474378) of intracranial B7H3-directed CAR-T cell therapy in patients with recurrent glioblastoma. B7H3-CART was delivered via intratumoral and intraventricular routes following surgical resection. The treatment showed manageable neurotoxicity and promising survival signals, with the recommended Phase II dose established. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Reena Thomas

The future of immunotherapy and AI approaches in glioblastoma
2:55
The future of immunotherapy and AI approaches in glioblastoma
Reena Thomas • 3 Jun 2025
Important considerations in developing CAR-T cell therapy for GBM
2:05
Important considerations in developing CAR-T cell therapy for GBM
Reena Thomas • 3 Jun 2025

Related Videos

TVI-AST-008: adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma
1:51
TVI-AST-008: adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma
Tolga Tuncer • 30 May 2026
Phase II trial of lutetium-177 dotatate in advanced intracranial meningioma
1:32
Phase II trial of lutetium-177 dotatate in advanced intracranial meningioma
Sylvia Kurz • 31 May 2026
Mechanism of 177Lu-dotatate in SSTR2-positive meningioma
1:04
Mechanism of 177Lu-dotatate in SSTR2-positive meningioma
Sylvia Kurz • 30 May 2026
Phase I trial of fb-PMT safety and tolerability in recurrent glioblastoma
3:54
Phase I trial of fb-PMT safety and tolerability in recurrent glioblastoma
Nicholas Blondin • 4 Jun 2026
The content of VJOncology is intended for healthcare professionals